Skip to main content

European collaborative project on Targeted therapy in renal cell cancer: genetic and tumor-related biomarkers for response and toxicity

Objective

Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical practice for patients with mRCC dramatically. Both response and toxicity to these expensive drugs is, however, extremely variable. With an increasing number of compounds becoming available, choice of compounds and sequence is becoming extraordinary challenging. Classical patient and tumor characteristics appear to have poor predictive ability. The aim of this project is to identify germline genetic markers that predict response and toxicity (by the use of high-resolution whole genome SNP arrays in groups of hundreds of patients treated with different agents), identify expression and epigenetic markers in tumors that predict response (by comparing expression and methylome arrays and kinase profiles in frozen tumor tissue from groups of patients who do (N=30) and do not (N=30) respond to different agents), to integrate these data from different platforms by means of bioinformatics and to conduct focused functional studies on the results in order to improve understanding of the critical molecular and resistance pathways involved. A large European consortium that has recruited and will recruit large numbers of patients ensures that the new markers identified in a first discovery phase can be tested in a subsequent replication phase. We have the ambition to define new validated risk stratification criteria to be used in personalized patient management. These criteria allow prediction of individual therapy response and resistance and will enable the monitoring of successful treatment outcome while reducing unnecessary drug use and expense.

Call for proposal

FP7-HEALTH-2010-two-stage
See other projects for this call

Coordinator

STICHTING RADBOUD UNIVERSITEIT
Address
Houtlaan 4
6525 XZ Nijmegen
Netherlands

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Wim Van Oijen (Mr.)
EU contribution
€ 1 792 400

Participants (14)

ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 258 000
Address
Albinusdreef 2
2333 ZA Leiden

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marlina Vos (Ms.)
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 19 152
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Keith Cann (Mr.)
UNIVERSITATSKLINIKUM JENA

Participation ended

Germany
EU contribution
€ 82 171,50
Address
Kastanienstr.1
07747 Jena

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kerstin Junker (Dr.)
CESAR CENTRAL EUROPEAN SOCIETY FOR ANTICANCER DRUG RESEARCH EWIV
Austria
EU contribution
€ 521 475
Address
Hanglussgasse 4 1 3
1150 Wien

See on map

Activity type
Research Organisations
Administrative Contact
Berta Moritz (Dr.)
ISLENSK ERFDAGREINING EHF
Iceland
EU contribution
€ 787 550
Address
Sturlugotu 8
101 Reykjavik

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bjorgvin Richardsson (Mr.)
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Spain
EU contribution
€ 550 000
Address
Avenida Gran Via Hospitalet 199-203
08908 L'hospitalet De Llobregat

See on map

Activity type
Research Organisations
Administrative Contact
Anaïs González (Ms.)
PAMGENE INTERNATIONAL BV
Netherlands
EU contribution
€ 471 500
Address
Wolvenhoek 10-12
5211 HH Den Haag

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martine Hulselmans (Ms.)
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
EU contribution
€ 373 200
Address
Plesmanlaan 121
1066 CX Amsterdam

See on map

Activity type
Research Organisations
Administrative Contact
Henri Van Luenen (Dr.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 80 000
Address
Rue De Tolbiac 101
75654 Paris

See on map

Activity type
Research Organisations
Administrative Contact
Muriel Bouas (Ms.)
UNIVERSITATEA DE MEDICINA SI FARMACIE CAROL DAVILA DIN BUCURESTI
Romania
EU contribution
€ 48 000
Address
Dionisie Lupu 37
020021 Bucuresti

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ioana Ciocan (Ms.)
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
Germany
EU contribution
€ 163 200
Address
Regina Pacis Weg 3
53113 Bonn

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Daniela Hasenpusch (Ms.)
Cambridge University Hospitals NHS Foundation Trust
United Kingdom
EU contribution
€ 327 648
Address
Hills Road Addenbrookes Hospital
CB2 0QQ Cambridge

See on map

Activity type
Other
Administrative Contact
Stephen Kelleher (Mr.)
GRUPO ESPANOL DE TRATAMIENTO DE TUMORES UROLOGICOS ASOCIACION
Spain
EU contribution
€ 97 125
Address
Calle Velazquez 7
28001 Madrid

See on map

Activity type
Research Organisations
Administrative Contact
Yasmina Bernabe (Mrs.)
UNIVERSITAT DES SAARLANDES
Germany
EU contribution
€ 428 128,50
Address
Campus
66123 Saarbrucken

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Vera Schneider (Dr.)